Document Type : Original Articles
- Arezoo Chouhdari 1, 2
- Farnaz Saberian 3
- Omidvar Rezaei 1
- Mohammad Samadian 1
- Kaveh Ebrahimzadeh 1
- Guive Sharifi 1
- Zahra Davoudi 1
1 Skull Base Research Center, Loghman Hakim Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 Social Determinants of Health Research Center, Amir-al-Momenin Hospital,Tehran Medical Sciences Branch, Islamic Azad University, Tehran, Iran
3 Department of Internal Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Background: The current study aimed to determine the quality of life (QoL) scores before and after treatment in patients with acromegaly.
Methods: In this longitudinal before-after study, the acromegaly quality of life (AcroQoL) questionnaire was used to assess the QoL. Demographics, clinical manifestations and co-morbidity data, pituitary axis involvement, biochemical and hormonal component tests, and health-related quality of life (HRQoL) before and after treatment (endoscopic transsphenoidal surgery, medication, radiotherapy) were evaluated in patients over 18 years of age. To compare the mean of continuous data, the independent t and Mann–Whitney tests were used. To compare the mean QOL score before and after the study, the paired-t and Wilcoxon tests were performed. The significance level was set at p<0.05.
Results: Among 80 patients with acromegaly who underwent trans-sphenoid surgery with or without radiotherapy or medication therapy with somatostatin analogs, 52 (65%) entered the remission phase within 6 months. Associations were found between the remission phase and female gender (p=0.004) and lower growth hormone (GH) (p=0.04) but not between remission and lower insulin-like growth factor-I (IGF1) after surgery (p=0.02) or gonadal axis disorder after treatment (p<0.001) statistically. Moreover, a significant association was found between not being in the remission phase and gonadal axis disorder before treatment (p=0.04). The QoL score in all dimensions of the AcroQoL questionnaire increased 6 months after treatment (p<0.001). Total AcroQoL score was higher after treatment in the remission group (p=0.03). The psychological scale had a significantly higher score both on the total scale (p<0.001) and on the two subscales of appearance (p<0.001) and personal relationship (p=0.003).
Conclusion: Because of the importance of QoL in acromegaly patients, further studies in this field are recommended.
- Geer EB, Sisco J, Adelman DT, Ludlam WH, Haviv A, Gelbaum D, et al. Observed discordance between outcomes reported by acromegaly patients and their treating endocrinology medical provider. Pituitary. 2020;23:140-8.
2. Polanco-Briceno S, Glass D, Plunkett C. Communication practices and awareness of resources for acromegaly patients among endocrinologists. Patient preference and adherence. 2016:2531-41.
3. Plunkett C, Barkan AL. The care continuum in acromegaly: how patients, nurses, and physicians can collaborate for successful treatment experiences. Taylor & Francis; 2015. p. 1093-9.
4. Matta MP, Couture E, Cazals L, Vezzosi D, Bennet A, Caron P.Impaired quality of life of patients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearance.
European journal of endocrinology. 2008;158(3):305-10.
5. Ezzat S, Caspar-Bell GM, Chik CL, Denis M-C, Domingue M-È,Imran SA, et al. Predictive markers for postsurgical medical management of acromegaly: a systematic review and consensus
treatment guideline. Endocrine Practice. 2019;25(4):379-93.
6. Geraedts VJ, Andela CD, Stalla GK, Pereira AM, Van Furth WR,Sievers C, et al. Predictors of quality of life in acromegaly: no consensus on biochemical parameters. Frontiers in endocrinology.2017;8:40.
7. Mercado M, Ramírez-Rentería C. Metabolic complications of acromegaly. InMetabolic Syndrome Consequent to Endocrine Disorders 2018 (Vol. 49, pp. 20-28). Karger Publishers.
8. Gadelha MR, Kasuki L, Lim DS, Fleseriu M. Systemic complications of acromegaly and the impact of the current treatment landscape: an update. Endocrine reviews. 2019;40(1):268-332.
9. Vandeva S, Yaneva M, Natchev E, Elenkova A, Kalinov K,Zacharieva S. Disease control and treatment modalities have impact on quality of life in acromegaly evaluated by Acromegaly Quality of Life (AcroQoL) Questionnaire. Endocrine. 2015;49:774-82.
10. Giustina A, Chanson P, Bronstein M, Klibanski A, Lamberts S,Casanueva F, et al. A consensus on criteria for cure of acromegaly.JClin Endocrinol Metab. 2010;95(7):3141-8.
11. Badia X, Webb SM, Prieto L, Lara N. Acromegaly quality of life questionnaire (AcroQoL). Health and quality of life outcomes.2004;2:1-6.
12. Gu J, Xiang S, He M, Wang M, Gu Y, Li L, et al. Quality of life in patients with acromegaly before and after transsphenoidal surgical resection. International journal of endocrinology.2020;2020.
13. Heidarnia M-A, Riazi-Isfahani S, Abadi A, Mohseni M. Cross cultural adaptation and assessing validity and reliability of SERVQUAL questionnaire in hospital service quality. Research
in medicine. 2014;38(2):98-105.
14. Webb SM, Badia X. Quality of life in acromegaly.Neuroendocrinology. 2016;103(1):106-11.
15. Trepp R, Everts R, Stettler C, Fischli S, Allemann S, Webb SM,et al. Assessment of quality of life in patients with uncontrolled vs. controlled acromegaly using the Acromegaly Quality
of Life Questionnaire (AcroQoL). Clinical endocrinology. 2005;63(1):103-10.
16. Webb SM, Badia X, Group NLSftSAS. Validity and clinical applicability of the acromegaly quality of life questionnaire, AcroQoL: a 6-month prospective study. European journal of
17. Fathalla H, Cusimano MD, Alsharif OM, Jing R. Endoscopic transphenoidal surgery for acromegaly improves quality of life.Canadian Journal of Neurological Sciences. 2014;41(6):735-41.
18. Webb SM. Quality of life in acromegaly. Neuroendocrinology.2006;83(3-4):224-9. 19. Gu J, Xiang S, He M, Wang M, Gu Y, Li L, et al. Quality of life in patients with acromegaly before and after transsphenoidal surgical resection. International journal of endocrinology.2020;2020.
20. González B, Vargas G, De Los Monteros ALE, Mendoza V,Mercado M. Persistence of diabetes and hypertension after multimodal treatment of acromegaly. The Journal of Clinical Endocrinology & Metabolism. 2018;103(6):2369-75
21. Wolters TL, Roerink SH, Drenthen LC, van Haren-Willems JH,Wagenmakers MA, Smit JW, et al. The course of obstructive sleep apnea syndrome in patients with acromegaly during
treatment. The Journal of Clinical Endocrinology & Metabolism.2020;105(1):290-304.
22. Parolin M, Dassie F, Alessio L, Wennberg A, Rossato M, Vettor R, et al. Obstructive sleep apnea in acromegaly and the effect of treatment: a systematic review and meta-analysis. The Journal of Clinical Endocrinology & Metabolism. 2020;105(3):e23-e31.
23. Kyriakakis N, Lynch J, Gilbey SG, Webb SM, Murray RD.Impaired quality of life in patients with treated acromegaly despite long-term biochemically stable disease: Results from a 5-years
prospective study. Clinical endocrinology. 2017;86(6):806-15.